NiKang Therapeutics Inc.

NiKang Therapeutics Inc.

is a clinical-stage biotechnology company founded in 2017 and based in Wilmington, Delaware. The company is dedicated to developing innovative small molecule drugs aimed at treating cancer and addressing significant medical needs. With a team of approximately 41 employees, NiKang focuses on drug discovery within the Healthcare & Life Sciences sector, striving to create first-in-class and best-in-class precision medicines. The company specializes in oncology drug discovery, utilizing insights from disease biology and structure-based drug design. NiKang has advanced three small molecule drugs into first-in-human clinical testing, targeting challenging oncology areas such as HIF2α, CDK2, and KRAS G12D. Their drug pipeline includes NKT2152, a HIF2α inhibitor, NKT3447, which targets CDK2-dependent cancer cells, and compounds designed to inhibit the KRAS G12D mutation. NiKang aims to provide transformative therapies for patients with advanced cancers, particularly those with clear cell renal cell carcinoma.